[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336571-105":59,"doc-detail-336571-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumor-dna-molecular-analyses-and-real-world-evidence-outcomes-of-fgfr2-amplified-gastroesophageal-cancers-abstract","Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers - Abstract","","Purpose: FGFR2b has emerged as a promising target alongside established biomarkers HER2 and PD-L1; this study characterizes the genomic landscape of FGFR2amp in gastroesophageal cancer (GEC) using a circulating tumor DNA (ctDNA) platform. Materials and Methods: 2017–2022 Guardant Health data were retrospectively analyzed in GEC patients with Guardant360 ctDNA NGS, comparing co-occurring alterations for FGFR2amp versus FGFR2null and integrating real-world and public datasets. Results: Under 4% had FGFR2amp; key co-mutations included TP53, CTNNB1, CDH1, and RHOA. Overall survival was 13.1 months. Conclusion: FGFR2 amplification defines clinically relevant subgroups, supporting ctDNA-driven refinement of targeted therapy development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-dna-molecular-analyses-and-real-world-evidence-outcomes-of-fgfr2-amplified-gastroesophageal-cancers-abstract/336571/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-molecular-analyses-and-real-world-evidence-outcomes-of-fgfr2-amplified-gastroesophageal-cancers-abstract/336571.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study purpose regarding FGFR2 in gastroesophageal cancer?","Question",{"text":112,"@type":113},"The study aims to elucidate the genomic landscape of FGFR2 amplification in gastroesophageal cancer using ctDNA, in addition to established biomarkers HER2 and PD-L1.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were FGFR2amp and FGFR2null groups identified and compared?",{"text":117,"@type":113},"Patients were retrospectively evaluated from 2017 to 2022 using Guardant Health’s Guardant360 ctDNA NGS, comparing co-occurring genetic alterations between FGFR2amp and FGFR2null and integrating real-world and public cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about FGFR2amp prevalence, co-mutations, and survival?",{"text":121,"@type":113},"Less than 4% of GEC patients in the Guardant Health database had FGFR2amp; the most common co-occurring mutations included TP53, CTNNB1, CDH1, and RHOA. In pooled institutional data, overall survival was reported as 13.1 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336571,1790875056,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers  \nBushra Shariff1, Reagan M. Barnett2, Farshid Dayyani3, Steven B. Maron4, Rory Mcgriskin4, Samuel Klempner5, Elifnur Yay Donderici2, Nicole Zhang2, Jude Masannat2, Leylah M. Drusbosky2, Rutika Mehta*, 1,  \n1 H. Lee Moffitt Cancer Center, Tampa, FL, USA, 2Guardant Health, Redwood City, CA, USA, 3University of California Irvine, Irvine, CA, USA,  \n4Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Massachusetts General Hospital, Boston, MA, USA  \n* Corresponding author: Rutika Mehta, MD, MPH, Department of GI Oncology, H. Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.([rutika.mehta@moffitt.org](rutika.mehta@moffitt.org)) .  \nAbstract  \nPurpose: In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that clinical evaluation of FGFR2 targeted therapy is underway, we sought to elucidate the genomic landscape of FGFR2amp in gastroesophageal cancer (GEC) using a circulating tumor DNA (ctDNA) platform.  \nMaterials and Methods: We retrospectively evaluated the Guardant Health database from 2017 to 2022 for patients with GECs with Guardant360 ctDNA next-generation sequencing (NGS) performed. We assessed co-occurring genetic alterations for patients who harbored FGFR2amp versus FGFR2null. We also explored real-world evidence database with Guardant Health, publicly available genomic databases (MSK cohort using cBioPortal), and pooled clinical data from large-volume cancer centers for FGFR2amp GECs.  \nResults: Less than 4% of patients with GEC in the Guardant Health database were identified to be FGFR2amp . The most commonly co-occurring gene mutations were TP53, CTNNB1, CDH1, and RHOA. Upon interrogation of the MSK cohort, these same genes were not significant on tissue NGS in the FGFR2amp cohort of GEC. In the pooled institutional cohort, we noted that FGFR2amp tumors were most commonly involving the gastroesophageal junction (GEJ) . The overall survival of these patients was noted at 13.1 months.  \nConclusion: FGFR2 is a validated target in GECs, and the contexture of FGFR2amp will be important in defining patient subgroups with responses to FGFR2-directed therapy. Using ctDNA to provide a more detailed genomic landscape in patients with GECs will allow the advancement of targeted therapy in the near future for these aggressive cancers.  \nKey words: FGFR2 amplification; gastroesophageal cancer; liquid biopsy; real-world data.  \nImplications for Practice  \nFGFR2 amplification is a marker of poor prognosis in gastroesophageal cancers (GECs), and clinical trials are underway to study FGFR2 inhibitors in GECs. The use of a circulating tumor DNA (ctDNA) platform has offered the advantage to study the genomic alterations at different time points during the treatment of cancer without necessarily needing repeat biopsies. This study highlights how the ctDNA platform can be used to identify GECs with FGFR2 amplification and describes the genomic alterations in FGFR2amp and FGFR2null GECs. The spectrum of co-occurring mutations was different when FGFR2amp cases were interrogated from tissue testing. There was a predominance of cell cycle pathway genes in the co-occurring mutations, which can potentially be harnessed for future combination treatment strategies. This is even more important as FGFR2 inhibitors make their way in the GEC treatment landscape.  \nIntroduction  \nThe fibroblast growth factor (FGF) pathway, including its receptors (FGFRs), regulates a broad spectrum of biological functions related to carcinogenesis. FGFRs 1-4 are transmembrane tyrosine kinase receptors with an extracellular domain  \nfor FGF ligand binding and an intracellular region that contains a tyrosine kinase motif and carboxy-terminal tail. The dimerization of the complex of FGF, FGFR, and heparin sulfate proteoglycans","cbCaiuNF9PtRxOna","https://ap.wps.com/l/cbCaiuNF9PtRxOna","pdf",6295725,"English","# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# Implications for Practice\n# Introduction","[{\"question\":\"What is the study purpose regarding FGFR2 in gastroesophageal cancer?\",\"answer\":\"The study aims to elucidate the genomic landscape of FGFR2 amplification in gastroesophageal cancer using ctDNA, in addition to established biomarkers HER2 and PD-L1.\"},{\"question\":\"How were FGFR2amp and FGFR2null groups identified and compared?\",\"answer\":\"Patients were retrospectively evaluated from 2017 to 2022 using Guardant Health’s Guardant360 ctDNA NGS, comparing co-occurring genetic alterations between FGFR2amp and FGFR2null and integrating real-world and public cohorts.\"},{\"question\":\"What were the key findings about FGFR2amp prevalence, co-mutations, and survival?\",\"answer\":\"Less than 4% of GEC patients in the Guardant Health database had FGFR2amp; the most common co-occurring mutations included TP53, CTNNB1, CDH1, and RHOA. In pooled institutional data, overall survival was reported as 13.1 months.\"}]","Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers - Abstract | PDF",1790015668,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62f9505ffcb8269146f05e633093c91c.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea7dd79e0325d1200c1a5e0655e0f977.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bb3ffd044daefd1b70e5a33704a82ec.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a1689b1050a69b33b13cfaa4cb066f0.webp",980,1287]